Folgen
Keine Story von Chiesi Farmaceutici S.p.A. mehr verpassen.

Chiesi Farmaceutici S.p.A.

Filtern
  • 30.01.2023 – 08:01

    Chiesi appoints Giuseppe Accogli as new Group CEO

    Parma, Italy (ots/PRNewswire) - - Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the Med-tech sector of reputed and complex companies such as Tyco Healthcare (Covidien), Baxter and Medtronic - "As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling the commitment to be a sustainable force for good in the biopharmaceutical ...

  • 22.09.2022 – 09:01

    Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025

    Parma, Italy (ots/PRNewswire) - - The Group has increased its B-Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019; - The recertification process by B Lab identifies further focus for action and continuous improvement. The B Corp movement, established to help companies balance profit with purpose, is growing by the day. Today ...

  • 01.04.2022 – 09:00

    CHIESI GROUP CONTINUES GROWTH

    Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...